SBI Securities Co. Ltd. Makes New $281,000 Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)

SBI Securities Co. Ltd. acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 7,130 shares of the company’s stock, valued at approximately $281,000.

A number of other large investors have also recently bought and sold shares of CRSP. ARK Investment Management LLC grew its stake in CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after buying an additional 1,474,439 shares in the last quarter. Baker BROS. Advisors LP grew its stake in CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after buying an additional 743,075 shares in the last quarter. State Street Corp boosted its stake in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of CRISPR Therapeutics by 5,269.3% in the 4th quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock valued at $3,267,000 after purchasing an additional 81,464 shares in the last quarter. Finally, KBC Group NV boosted its stake in shares of CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock valued at $2,382,000 after purchasing an additional 57,696 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director John Greene acquired 7,000 shares of the stock in a transaction dated Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the purchase, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $43.84 on Thursday. CRISPR Therapeutics AG has a 52-week low of $36.52 and a 52-week high of $83.50. The firm has a 50 day moving average price of $42.57 and a two-hundred day moving average price of $45.86. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of -10.03 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Citigroup reduced their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research note on Tuesday, February 18th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, Truist Financial raised their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.